# A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

> **NCT00720382** · PHASE3 · COMPLETED · sponsor: **Meda Pharmaceuticals** · enrollment: 703 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** 0.15% azelastine hydrochloride
- **DRUG:** Mometasone furoate

## Key facts

- **NCT ID:** NCT00720382
- **Lead sponsor:** Meda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-06
- **Final completion:** 2008-07
- **Target enrollment:** 703 (ACTUAL)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720382, "A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00720382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*